Genmab — Maj 2024
-
Godmorgen
-
Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment https://proinvestor.com/investornyt/1164760/sanofis-sarclisa-granted-fda-priority-review-for-transplant-ineligible-multiple-myeloma-treatment
-
Fra Nordeas morgenkommentar: Genmab (hold) - Sanofi har fået FDA priority review for deres CD38 antistof Sarclisa i MM (knoglemarvskræft). Hidtil har den kommercielle succes for Sarclisa været meget begrænset i de senere linjer af MM. Nu nærmer Sanofi sig en godkendelse i frontlinje behandling med Sarclisa (nydiagnosticerede MM-patienter), hvor det skal konkurrere direkte mod Darzalex/Faspro. Såfremt det godkendes, bliver det det første antistof, som skal konkurrere mod Darzalex/Faspro i
-
frontlinje behandling med Sarclisa (nydiagnosticerede MM-patienter), hvor det skal konkurrere direkte mod Darzalex/Faspro. Såfremt det godkendes, bliver det det første antistof, som skal konkurrere mod Darzalex/Faspro i frontline. En godkendelse i US kommer sandsynligvis ultimo september 2024 med en forventet lancering umiddelbart efter. Aktien faldt 5% i fredags. ASCO abstracts viste rimelige tidlige responsrater (21-22% overall responsrate) i fase II studiet med GEN1046 (ACASUNLIMAB), men
-
lever tox er et issue, og det fik primær fokus. Der er noget på leveren, især når man ser på high dose armen, som er den, de kører videre med i fase III. Data cut-off var tilbage i begyndelsen af januar, mens de data, der præsenteres på ASCO (konferencen løber fra 31/5 til 4/6), vil være mere modne med et data cut-off sandsynligvis omkring midten til slutningen af maj (det vil forbedre data).
-
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
- 'with the highest ORR for GEN1042 plus chemoimmunotherapy.' Have we seen data there??
-
-
- bying cheep stocks, 2) get ahead of competition, 3) if this works broadly in many solid tumours they probably need BP to carry this though and deal could be done based on this study with more than a 1000 patients. This is of cause very speculative
- bying cheep stocks, 2) get ahead of competition, 3) if this works broadly in many solid tumours they probably need BP to carry this though and deal could be done based on this study with more than a 1000 patients. This is of cause very speculative
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind